Pre-made Duvortuxizumab benchmark antibody ( Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-161

Pre-made Duvortuxizumab benchmark antibody (Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-161-1mg 1mg Inquiry
GMP-Bios-ab-161-10mg 10mg Inquiry
GMP-Bios-ab-161-100mg 100mg Inquiry
GMP-Bios-ab-161-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody
INN Name Duvortuxizumab
FormatBispecific scFv with Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2016
Year Recommended2017
CompaniesJanssen Biotech;MacroGenics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma
Development TechDual-Affinity Re-Targeting Technology